Allogene Therapeutics Inc (NAS:ALLO)
$ 2.99 -0.01 (-0.33%) Market Cap: 625.25 Mil Enterprise Value: 269.70 Mil PE Ratio: 0 PB Ratio: 1.22 GF Score: 34/100

Q2 2024 Allogene Therapeutics Inc Earnings Call Transcript

Aug 07, 2024 / 09:00PM GMT
Release Date Price: $2.47 (-3.14%)
Operator

Hello, and thank you for standing by. Welcome to Allogene Therapeutics second quarter 2024 conference call. (Operator Instructions)

I would now like to turn the call over to Christine Cassiano. You may begin.

Christine Cassiano
Allogene Therapeutics Inc - Executive Vice President, Chief Corporate Affairs and Brand Strategy Officer

Thank you, operator, and welcome to all who have joined this call. After the market closed today, Allogene issued a press release that provides a business update and financial results for the second quarter of 2024. This press release and today's webcast are available on our website.

Following our prepared remarks, we will host a Q&A session. We recognize that historically questions have been multifaceted but note that we will endeavor to keep this call to under an hour. Joining me today are Dr. David Chang, President and Chief Executive Officer; Dr. Zachary Roberts, Executive Vice President of Research and Development and Chief Medical Officer; and Geoff Parker, Chief Financial Officer.

During today

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot